FDA approves Janssen's fast-acting depression therapy esketamine

FDA approved Spravato esketamine from Janssen Pharmaceuticals Inc. late Tuesday to treat adult patients with treatment-resistant depression.

Spravato is designed to be effective within days rather than weeks. A spokesperson for the Johnson & Johnson (NYSE:JNJ) unit told BioCentury the wholesale acquisition cost (WAC) for the 56 mg dose of Spravato will be $590, and the 84 mg dose will cost $885...